3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
24
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Neuroblastoma
4
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
pembrolizumab
9
avelumab
8
Nivolumab
6
Ipilimumab
4
Radiotherapy
3
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Specimen Handling
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Interferon-beta
2
Cyclophosphamide
2
Biopsy
2
Bevacizumab
2
tremelimumab
1
sargramostim
1
sapanisertib
1
regorafenib
1
prednylidene
1
poly ICLC
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
deltacortene
1
decitabine and cedazuridine drug combination
1
bempegaldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Merkel Cell
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled